Institution
University of Kansas
Education•Lawrence, Kansas, United States•
About: University of Kansas is a education organization based out in Lawrence, Kansas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 38183 authors who have published 81381 publications receiving 2986312 citations. The organization is also known as: KU & Univ of Kansas.
Topics: Population, Poison control, Large Hadron Collider, Health care, Cancer
Papers published on a yearly basis
Papers
More filters
••
Northwestern University1, Veterans Health Administration2, University of Nebraska Omaha3, University of Pennsylvania4, University of California, San Francisco5, University of Michigan6, National Institutes of Health7, University of Kansas8, Oregon Health & Science University9, Portland VA Medical Center10, United States Department of Veterans Affairs11, Baylor College of Medicine12, Virginia Commonwealth University13, University of Iowa14
TL;DR: Deep brain stimulation was more effective than best medical therapy in improving on time without troubling dyskinesias, motor function, and quality of life at 6 months, but was associated with an increased risk of serious adverse events.
Abstract: Context Deep brain stimulation is an accepted treatment for advanced Parkinson disease (PD), although there are few randomized trials comparing treatments, and most studies exclude older patients. Objective To compare 6-month outcomes for patients with PD who received deep brain stimulation or best medical therapy. Design, Setting, and Patients Randomized controlled trial of patients who received either deep brain stimulation or best medical therapy, stratified by study site and patient age ( Intervention Bilateral deep brain stimulation of the subthalamic nucleus (n = 60) or globus pallidus (n = 61). Patients receiving best medical therapy (n = 134) were actively managed by movement disorder neurologists. Main Outcome Measures The primary outcome was time spent in the “on” state (good motor control with unimpeded motor function) without troubling dyskinesia, using motor diaries. Other outcomes included motor function, quality of life, neurocognitive function, and adverse events. Results Patients who received deep brain stimulation gained a mean of 4.6 h/d of on time without troubling dyskinesia compared with 0 h/d for patients who received best medical therapy (between group mean difference, 4.5 h/d [95% CI, 3.7-5.4 h/d]; P Conclusion In this randomized controlled trial of patients with advanced PD, deep brain stimulation was more effective than best medical therapy in improving on time without troubling dyskinesias, motor function, and quality of life at 6 months, but was associated with an increased risk of serious adverse events. Trial Registration clinicaltrials.gov Identifier: NCT00056563
1,218 citations
••
University of Leeds1, Jet Propulsion Laboratory2, University of Colorado Boulder3, Technical University of Denmark4, Durham University5, University of Texas at Austin6, Ohio State University7, University College London8, Technische Universität München9, Lamont–Doherty Earth Observatory10, Johns Hopkins University Applied Physics Laboratory11, Newcastle University12, University of Tasmania13, Utrecht University14, University of Kansas15, Swansea University16, Goddard Space Flight Center17, University of Ottawa18, University of California, Irvine19, University of Bristol20, British Antarctic Survey21, University of Innsbruck22, Delft University of Technology23
TL;DR: There is good agreement between different satellite methods—especially in Greenland and West Antarctica—and that combining satellite data sets leads to greater certainty, and the mass balance of Earth’s polar ice sheets is estimated by combining the results of existing independent techniques.
Abstract: We combined an ensemble of satellite altimetry, interferometry, and gravimetry data sets using common geographical regions, time intervals, and models of surface mass balance and glacial isostatic adjustment to estimate the mass balance of Earth’s polar ice sheets. We find that there is good agreement between different satellite methods—especially in Greenland and West Antarctica—and that combining satellite data sets leads to greater certainty. Between 1992 and 2011, the ice sheets of Greenland, East Antarctica, West Antarctica, and the Antarctic Peninsula changed in mass by –142 ± 49, +14 ± 43, –65 ± 26, and –20 ± 14 gigatonnes year−1, respectively. Since 1992, the polar ice sheets have contributed, on average, 0.59 ± 0.20 millimeter year−1 to the rate of global sea-level rise.
1,215 citations
••
Yale Cancer Center1, University of Toronto2, Princess Margaret Cancer Centre3, Osaka University4, University of Kansas5, University of Pittsburgh6, Indiana University7, NewYork–Presbyterian Hospital8, Pontifical Catholic University of Chile9, Sheba Medical Center10, Tel Aviv University11, University of California, Los Angeles12, University of Chicago13, Tel Aviv Sourasky Medical Center14, Sanford Health15, University of California, San Francisco16, Memorial Sloan Kettering Cancer Center17, Harvard University18, New Generation University College19, Merck & Co.20, Mayo Clinic21
TL;DR: Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment.
Abstract: Importance Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety and efficacy of pembrolizumab in a cohort of patients with previously treated gastric or gastroesophageal junction cancer. Design, Setting, and Participants In the phase 2, global, open-label, single-arm, multicohort KEYNOTE-059 study, 259 patients in 16 countries were enrolled in a cohort between March 2, 2015, and May 26, 2016. Median (range) follow-up was 5.8 (0.5-21.6) months. Intervention Patients received pembrolizumab, 200 mg, intravenously every 3 weeks until disease progression, investigator or patient decision to withdraw, or unacceptable toxic effects. Main Outcomes and Measures Primary end points were objective response rate and safety. Objective response rate was assessed by central radiologic review per Response Evaluation Criteria in Solid Tumors, version 1.1, in all patients and those with programmed cell death 1 ligand 1 (PD-L1)–positive tumors. Expression of PD-L1 was assessed by immunohistochemistry. Secondary end points included response duration. Results Of 259 patients enrolled, most were male (198 [76.4%]) and white (200 [77.2%]); median (range) age was 62 (24-89) years. Objective response rate was 11.6% (95% CI, 8.0%-16.1%; 30 of 259 patients), with complete response in 2.3% (95% CI, 0.9%-5.0%; 6 of 259 patients). Median (range) response duration was 8.4 (1.6+ to 17.3+) months (+ indicates that patients had no progressive disease at their last assessment). Objective response rate and median (range) response duration were 15.5% (95% CI, 10.1%-22.4%; 23 of 148 patients) and 16.3 (1.6+ to 17.3+) months and 6.4% (95% CI, 2.6%-12.8%; 7 of 109 patients) and 6.9 (2.4 to 7.0+) months in patients with PD-L1–positive and PD-L1–negative tumors, respectively. Forty-six patients (17.8%) experienced 1 or more grade 3 to 5 treatment-related adverse events. Two patients (0.8%) discontinued because of treatment-related adverse events, and 2 deaths were considered related to treatment. Conclusions and Relevance Pembrolizumab monotherapy demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment. Durable responses were observed in patients with PD-L1–positive and PD-L1–negative tumors. Further study of pembrolizumab for this group of patients is warranted. Trial Registration clinicaltrials.gov Identifier: NCT02335411
1,203 citations
••
TL;DR: The modified hydroxyproline assay presented in this communication will be useful for routine measurement of collagen content in extracts of various tissue specimens and can be used for batch processing of column fractions to monitor the collagen concentrations during purification.
1,196 citations
••
University of British Columbia1, University of Maryland, Baltimore2, University of Wollongong3, University of Pennsylvania4, University of Illinois at Urbana–Champaign5, University of Kansas6, University of California, San Diego7, University of California, Los Angeles8, Massey University9, Washington State University10, University of Oklahoma11, University of Iowa12
TL;DR: This article provides a modern summary of the characteristics defining habituation, and can serve as a convenient primer for those whose research involves stimulus repetition.
1,196 citations
Authors
Showing all 38401 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gordon H. Guyatt | 231 | 1620 | 228631 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
Wei Li | 158 | 1855 | 124748 |
David Tilman | 158 | 340 | 149473 |
Tomas Hökfelt | 158 | 1033 | 95979 |
Pete Smith | 156 | 2464 | 138819 |
Daniel J. Rader | 155 | 1026 | 107408 |
Melody A. Swartz | 148 | 1304 | 103753 |
Kevin Murphy | 146 | 728 | 120475 |
Carlo Rovelli | 146 | 1502 | 103550 |
Stephen Sanders | 145 | 1385 | 105943 |
Marco Zanetti | 145 | 1439 | 104610 |
Andrei Gritsan | 143 | 1531 | 135398 |
Gunther Roland | 141 | 1471 | 100681 |
Joseph T. Hupp | 141 | 731 | 82647 |